Amicus Therapeutics (FOLD) Sees IPO Pricing Between $14-16 Per Share
Tweet Send to a FriendGet Alerts FOLD Hot Sheet
Up)
Trade FOLD Now!
Amicus Therapeutics (Nasdaq: FOLD) has filed an amended S-1 statement with the SEC. The Company expects the public offering price to be between $14.00-16.00 per share. The Company is offering 5.0 million shares. The company plans to list on the Nasdaq Global Market under the symbol "FOLD".
The offering is being made through JPMorgan, Morgan Stanley, Merrill Lynch, Lazard Capital and Pacific Growth Equities.
Amicus Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
The offering is being made through JPMorgan, Morgan Stanley, Merrill Lynch, Lazard Capital and Pacific Growth Equities.
Amicus Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
You May Also Be Interested In
- Friday's Hot IPOs Get Even Hotter (MKTO) (DATA)
- Tableau Software (DATA) IPO Surges Higher
- UBIC (UBIC) IPO Trades Lower
Create E-mail Alert Related Categories
IPOs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
